Silver Spring-based biotech United Therapeutics Corp. (NASDAQ: UTHR) lost a recent challenge to one of its lead patents for its flagship drugs.
The U.S. Patent and Trademark Office's Patent Trial and Appeal Board found that all of the local company's claims for the particular patent — which impacts its lead products for treating pulmonary arterial hypertension such as Remodulin, Tyvaso and Orenitram — are not patentable.